Structure Therapeutics Valuation
| GPCR Stock | 70.07 1.97 2.73% |
At this time, the company appears to be undervalued. Structure Therapeutics has a current Real Value of USD82.03 per share. The regular price of the company is USD70.07. Our model measures the value of Structure Therapeutics from inspecting the company fundamentals such as Price To Book of 6.43 X, shares outstanding of 70.64 M, and Return On Equity of -0.25 as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Structure Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Structure Therapeutics is based on 3 months time horizon. Increasing Structure Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Structure stock is determined by what a typical buyer is willing to pay for full or partial control of Structure Therapeutics American. Since Structure Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Structure Stock. However, Structure Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 70.07 | Real 82.03 | Hype 72.42 |
The intrinsic value of Structure Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Structure Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Structure Therapeutics American helps investors to forecast how Structure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Structure Therapeutics more accurately as focusing exclusively on Structure Therapeutics' fundamentals will not take into account other important factors: About Structure Therapeutics Valuation
The stock valuation mechanism determines Structure Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Structure Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Structure Therapeutics. We calculate exposure to Structure Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Structure Therapeutics's related companies.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.